secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dermata Therapeutics, Inc. (DRMA)
CIK:        0001853816
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001641172-25-023570
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dermata reports positive Phase 3 STAR-1 data, Q2 2025 cash $6.5M
----------------------------------------------------------------

- XYNGARI™ Phase 3 STAR-1 met all three co-primary endpoints with statistical significance at weeks 4 and 12.
- Raised $8.8M gross proceeds in H1 2025; cash $6.5M at June 30, expected to fund operations into Q2 2026.
- R&D expenses $0.6M in Q2 2025 vs $2.0M in Q2 2024, decrease due to STAR-1 completion.
- G&A expenses $1.2M in Q2 2025 vs $0.9M in Q2 2024; increase from compliance and personnel costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1853816/000164117225023570/0001641172-25-023570-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1853816/000164117225023570/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-023570

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer